

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
March 19, 2020
WEBEX ONLY

Committee Members Present

Conrad Balcer, DO
Jennifer Kemp-Oestreich, Pharm D
Laura Kingsley, Pharm D
Morgan Sperry, Pharm D
Matthew Stinson

MO HealthNet Staff Present:

Josh Moore, Director of Pharmacy
Mark Roaseau, R.Ph, Clinical Pharmacist
Elizabeth Sissom, RN, Clinical
Management
Angela Wilson, Pharmacy Operations
Manager
Carmen Burton, Administrative Assistant
Dr. Timothy Kling, MD, Assistant Medical
Director
Lisa E. Smith, Program Development
Specialist
Jackie Hickman, Drug Rebate Unit
Supervisor
Keri Ballew, Drug Rebate Medicaid
Specialist
Connie Sutter, Fiscal Manager
Elizabeth Short, Program Specialist

Contractors in Attendance:

Luke Boehmer,	Conduent
Jennifer Colozza,	Conduent
Megan Fast,	Conduent
Olivia Push,	Conduent
Janelle Sheen,	Conduent
Valerie Schmitz,	Wipro
Geri Roling,	Wipro
Chelsea Pendleton,	Wipro
Valerie Schmitz,	Wipro

Others Attending:

This meeting is WebEx only. No sign in sheets.

Welcome, Introductions and Opening Remarks	Conrad Balcer, Chair, called the meeting to order. Josh Moore introduced himself and started the introductions and opening remarks.
Minutes Approval	Minutes of the December 2019 Drug PA meeting were reviewed and approved. Morgan Sperry made the motion and Jennifer Kemp-Oestreich second the motion.
Pharmacy Program/Budget Update	Josh Moore presented a brief power point due to phone issues at MO HealthNet. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking. Josh also talked about Covid19 and early refills and overrides.
Old Business	
Old Business Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided to the board members by email. Schedules may be found on the MHD web page at https://dss.mo.gov/mhd/cs/pharmacy/pdf/impsched.pdf
New Business	
New Drug Review	<p>Josh Moore reviewed the new products identified for the quarter and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> ● Discussion – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was emailed to the Members' for discussion and action. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept the new product recommendations as presented. (See Roll Call Vote)
Clinical Edits	
Acne or Rosacea – Select Topical Agents Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for the new clinical edit. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Clobazam Agents Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for annual review. One change of adding a document diagnosis to the criteria. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as with one change made. (See Roll Call Vote)

DMD Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the new criteria document with an added update with a new drug. ● Public Hearing – There was one Public Speaker. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Epidiolex Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for annual review. No other changes at this time. ● Public Hearing – There was one Public Speaker. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Galafold Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for annual review. No changes to criteria at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Givlaari Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document and proposing no document changes in this class. ● Public Hearing – There was one Public Speaker. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Megestrol Acetate Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for the new clinical edit. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Nocturnal Polyuria Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Reblozyl Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Sickle Cell Disease Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document for the new clinical edit. ● Public Hearing – There were two Public Speakers. ● Decision – The Committee voted to accept this Clinical Edit with changes made to modify the bullet edits. (See Roll Call Vote)
Spravato Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document and a healthcare provider administers it. ● Public Hearing – There was one Public Speaker. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)
Systemic Antifungals Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document and recommended no changes at this time to the edit. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this Clinical Edit as presented. (See Roll Call Vote)

Preferred Drug List (PDL)	
Actinic Keratosis Agents – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria and recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Androgenic Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria documents suggested one new agents and recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antibiotics – Inhaled Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document and recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antifungal Agents - Oral	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria and recommended no changes to be made at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antifungal Agents – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines - Intranasal	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria and recommended no changes to the preferred and non-preferred agents. Updated the age to 6 years old from 12 years old and recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines - Ophthalmic	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antihistamines/Decongestant Combinations – Low Sedating (2nd Generation)	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document and added one new agent. Would like a clinical consultation due to the cost being much higher before it is approved. No other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Antiparasitic Agents – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, one new non-preferred agent that was preferred agent. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiviral Agents – Herpes Oral	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Antiviral Agents – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, Abreva is now a non-preferred agent. Recommended no other changes to preferred and non-preferred agents at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Atopic Dermatitis Agents – Immunomodulators	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes to preferred and non-preferred agents at this time. Made changes to the approval criteria. ● Public Hearing – There was one Public Speaker. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Benzoyl Peroxide/Antibiotic Combinations	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta-Adrenergic Agents – Long Acting	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta-Adrenergic Agents – Nebulized	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Beta-Adrenergic Agents – Short Acting	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to preferred and non-preferred agents. Recommended no further changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
COPD Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to preferred and non-preferred agents. Recommended no further changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Corticosteroids – Inhaled	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids – Ophthalmic “Soft” Steroids	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to the non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to the preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Corticosteroids and Rhinitis Agents – Intranasal	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Cough and Cold Preparations	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, made changes in the appendix and will not get into effect until the end of June 2020. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Epinephrine Self-Injectable Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Fluoroquinolones – Ophthalmic	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to the preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Fluoroquinolones – Otic	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to the preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Glaucoma Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to the preferred and non-preferred agents and to the criteria. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Leukotriene Receptor Modifiers	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Mast Cell Stabilizers – Ophthalmic	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
NSAIDs – Ophthalmic	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Pancreatic Enzyme Agents	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Psoriasis Agents – Oral	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, recommended no changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Psoriasis Agents – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed preferred and added to the non-preferred agents and criteria. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Retinoids – Topical	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed preferred and added to the non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Ulcerative Colitis Agents – Oral	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)
Ulcerative Colitis Agents - Rectal	<ul style="list-style-type: none"> ● Discussion – Josh Moore reviewed the criteria document, reviewed changes to preferred and non-preferred agents. Recommended no other changes at this time. ● Public Hearing – No Public Comment. ● Decision – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)

Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf
Conduent Update	Conduent did present the following items for review. These items were included in the packet for the meeting. Here is the list: <ul style="list-style-type: none"> • Helpdesk Status Report • User Statistics • New Drug Summary • Logging Information
Program Utilization: Top 25 Drugs Summary	The Top 25 Drugs Summary Reports for the 1 quarter of fiscal year 2020 were provided in the packets for review. Two versions were provided: one report ranked drug spend by dollars and the other by utilization/claims.
Adjourn	The meeting was adjourned pursuant to Section 610.021 Subsection (14), (5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees. (See attached roll call) The next meeting of the Drug Prior Authorization Committee is scheduled for June 18, 2020 at Department of Natural Resources, 1101 Riverside Dr., Lacharette/Nightingale Rooms, Jefferson City, MO 65101.

ROLL CALL FOR DRUG PA March 19, 2020

<u>Member</u>	Minutes	New Drugs	Acne or Rosacea – Select Topical Agents	Clobazam Agents	DMD	Epidiolex
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	MY	Y	SY	SY	Y	MY
Laura Kingsley, Pharm D	Y	Phone issue	Phone issue	Y	MY	SY
Jennifer Kemp- Oestreich, Pharm D	SY	MY	MY	MY	SY	Y
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	Y	SY	Y	Y	Y	Y
<u>Member</u>	Galafold	Givlaari	Megestrol Acetate	Nocturnal Polyuria	Reblozyl	Sickle Cell Disease
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	Y	Y	MY	MY	SY	SY
Laura Kingsley, Pharm D	Phone issue	SY	Y	Y	Y	Y
Jennifer Kemp- Oestreich, Pharm D	MY	MY	Y	SY	MY	MY
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	SY	Y	SY	Y	Y	A

<u>Member</u>	Spravato	Systemic Antifungals	Actinic Keratosis Agents – Topical (PDL EDITS)	Androgenic Agents	Antibiotics – Inhaled Agent	Antifungal Agents – Oral
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	MY	Y	SY	SY	MY	Y
Laura Kingsley, Pharm D	SY	SY	MY	Y	SY	MY
Jennifer Kemp-Oestreich, Pharm D	Y	MY	Y	MY	Y	SY
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A
<u>Member</u>	Antifungal Agents – Topical	Antihistamines – Intranasal	Antihistamines – Ophthalmic	Antihistamines/ Decongestant Combinations – Low Sedating (2 nd Generation)	Antiparasitic Agents – Topical	Antiviral Agents – Herpes Oral
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	MY	Y	SY	Y	MY	SY
Laura Kingsley, Pharm D	SY	SY	Y	SY	SY	MY
Jennifer Kemp-Oestreich, Pharm D	Y	MY	MY	MY	Y	Y
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A

<u>Member</u>	Antiviral Agents – Topical	Atopic Dermatitis Agents – Immunomodulators	Benzoyl Peroxide/Antibiotic Combinations	Beta-Adrenergic Agents – Long Acting	Beta-Adrenergic Agents – Nebulized	Beta-Adrenergic Agents – Short Acting
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	Y	Y	SY	MY	SY	Y
Laura Kingsley, Pharm D	MY	MY	MY	SY	Y	MY
Jennifer Kemp-Oestreich, Pharm D	SY	SY	Y	Y	MY	SY
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A
<u>Member</u>	COPD Agents	Corticosteroids – Inhaled	Corticosteroids – Ophthalmic “Soft” Steroids	Corticosteroids – Topical	Corticosteroids and Rhinitis Agents – Intranasal	Cough and Cold Preparations
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	SY	Y	Y	MY	MY	MY
Laura Kingsley, Pharm D	Y	SY	SY	Y	SY	SY
Jennifer Kemp-Oestreich, Pharm D	MY	MY	MY	SY	Y	Y
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A

<u>Member</u>	Epinephrine Self-Injectable Agents	Fluoroquinolones – Ophthalmic	Fluoroquinolones – Otic	Glaucoma Agents	Leukotriene Receptor Modifiers	Mast Cell Stabilizers – Ophthalmic
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	SY	Y	MY	SY	Y	MY
Laura Kingsley, Pharm D	Y	MY	Y	MY	SY	SY
Jennifer Kemp-Oestreich, Pharm D	MY	SY	SY	Y	MY	Y
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A
<u>Member</u>	NSAIDs – Ophthalmic	Pancreatic Enzyme Agents	Psoriasis Agents – Oral	Psoriasis Agents – Topical	Retinoids – Topical	Ulcerative Colitis Agents – Oral
Conrad Balcer, DO	Y	Y	Y	Y	Y	Y
Morgan Sperry, Pharm D	SY	MY	Y	MY	SY	SY
Laura Kingsley, Pharm D	MY	Y	SY	SY	MY	Y
Jennifer Kemp-Oestreich, Pharm D	Y	SY	MY	Y	Y	MY
Angeline Stanislaus	A	A	A	A	A	A
Matthew Stinson, MD	A	A	A	A	A	A

<u>Member</u>	Ulcerative Colitis Agents - Rectal	Motion To Close/Meeting Adjourned				
Conrad Balcer, DO	Y	Y				
Morgan Sperry, Pharm D	MY	MY				
Laura Kingsley, Pharm D	SY	Y				
Jennifer Kemp-Oestreich, Pharm D	Y	SY				
Angeline Stanislaus	A	A				
Matthew Stinson, MD	A	A				

Roll Call Abbreviations:**A-Absent****AL-Alternate****R-Ratify****M-Motion****S-Second****Y-Yes to the vote**